Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00271232 · ClinicalTrials.gov registry record · NA

InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System

A NA study of Heart Failure, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

Completed
Registry status
NA
Development phase
238
Enrollment target
20
Study locations

NCT00271232: Completed NA study of Heart Failure, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

NCT00271232 is a NA study of Heart Failure that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 238 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00271232, a NA study of Heart Failure, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

COMPLETED
Registry status
NA
Development phase
238 participants
Enrollment target
20
Study locations

Study Summary

People who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (ICD). An ICD is implanted surgically just under the skin in the upper chest area and it sends a strong electrical impulse, or shock, to the heart to return it to a normal rhythm. If the heart is beating too slowly or at an abnormal rhythm, an ICD can also pace the heart to return the heart to its normal rhythm. The InSync III Marquis device can change the timing of when the left and right ventricles of the heart are paced to beat. This is called "V to V timing". V to V timing may further improve the pumping function of the heart. The purpose of this study is to determine whether or not this V to V timing feature of the InSync III Marquis system is safe and effective.

Conditions Studied

Heart Failure

Interventions

  • DEVICE Cardiac resynchronization therapy

Study Locations (20)

Florida

  • - Jacksonville
  • - Pensacola
  • - Tampa

New York

  • - New York
  • - Rochester
  • - Syracuse

California

  • - Los Angeles
  • - Stanford

Minnesota

  • - Minneapolis
  • - Saint Paul

Alaska

  • - Anchorage

Arizona

  • - Phoenix

Georgia

  • - Atlanta

Indiana

  • - Beech Grove

Trial Details

FieldValue
Enrollment Target 238 participants
Start Date 2003-03
Est. Completion 2005-04
Phase NA

Sponsor

Medtronic Cardiac Rhythm and Heart Failure

115 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00271232

The ClinicalTrials.gov registry entry for NCT00271232 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (88% lower). The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Cardiac resynchronization therapy is the first listed.

NCT00271232 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, New York, California.

Frequently Asked Questions

What is clinical trial NCT00271232 about?

NCT00271232 is a clinical study titled "InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System". People who have a dangerously fast heart beat, or whose heart is at risk of stopping beating, may be in need of an electronic device called an implantable cardioverter defibrillator (ICD). An ICD is implanted surgically just under the skin in the upper chest area and it sends a strong electrical imp...

What is the current status of trial NCT00271232?

This trial is currently completed. It is a NA study. The enrollment target is 238 participants. The study started on 2003-03. Estimated completion is 2005-04.

What conditions does trial NCT00271232 study?

This clinical trial studies the following conditions: Heart Failure.

What interventions are being tested in trial NCT00271232?

The interventions under investigation include: Cardiac resynchronization therapy (DEVICE).

Who is sponsoring clinical trial NCT00271232?

This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00271232 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.